Search

Displaying results 3641 - 3650 of 10000 in total
  1. Drug

    KW-7158

    go.drugbank.com/drugs/DB05498
    Experimental

    The therapeutic effects of KW-7158 in overactive bladder may be due to the activation of A-type K(+) channels which regulate afferent neuron excitability and firing properties in the dorsal root ganglion

  2. Drug

    Atl146e

    go.drugbank.com/drugs/DB05191
    Investigational

    ATL146e is an anti-inflammatory compounds which is an agonist of A2A adenosine receptors.

  3. Drug

    T611

    go.drugbank.com/drugs/DB06391
    Experimental

    T611 is an investigational oral anti-cytomegalovirus (CMV) drug candidate.

  4. Drug

    Tedizolid

    go.drugbank.com/drugs/DB14569
    ApprovedInvestigational

    This product is currently available as both an oral tablet and as a powder for intravenous injection.[L11232] … [L11232, A199086, A199050] Tedizolid was approved by the FDA on June 20, 2014, for sale by Cubist Pharmaceuticals as tedizolid phosphate (SIVEXTRO®).

  5. Drug

    CMC 001

    go.drugbank.com/drugs/DB05353
    Investigational

    CMC 001 is an orally administered MRI contrast agent in development for enhancement of the liver, bile ducts and gastrointestinal tract.

  6. Drug

    Methylergometrine

    go.drugbank.com/drugs/DB00353
    ApprovedInvestigational

    (Merck Index, 11th ed)

    Synonyms: 9,10-Didehydro-N-[1-(hydroxymethyl)-propyl]-D-lysergamide
  7. Drug

    Phloroglucinol

    go.drugbank.com/drugs/DB12944
    Investigational

    Phloroglucinol has been used in trials studying the diagnostic of Colonoscopy.

    Categories: Compounds used in a research, industrial, or household setting
  8. Drug

    Oxtriphylline

    go.drugbank.com/drugs/DB01303
    Approved

    In the US, oxtriphylline is no longer available. … Once in the body, theophylline is released and acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator.

  9. Drug

    Palifermin

    go.drugbank.com/drugs/DB00039
    ApprovedInvestigational

    It is 140 residues long, and is produced using E. coli. Palifermin was granted FDA approval on 15 December 2004.[L17933]

  10. Drug

    TRX1

    go.drugbank.com/drugs/DB05863
    Experimental

    TRX1 is a humanized antibody that binds to the CD4 receptor found on a subset of T cells. … TRX1 is being developed for the potential treatment of autoimmune diseases in collaboration with Genentech, Inc. TolerRx is currently conducting a Phase I clinical study of TRX1 in the United Kingdom.